Dr Reddy’s Laboratories is targeting to launch its new treatment alternatives for Covid-19 patients that are currently under-development
Bengaluru: In a positive development, Dr Reddy’s Laboratories is targeting to launch its new treatment alternatives for Covid-19 patients that are currently under-development.
Swarajya adds that Dr Reddy’s has the rights for the first 250 million doses of the same in India and the initial quantities are set to come through the imported route from Russia. Additionally, it has forged partnerships with around six manufacturing firms in order to produce the same locally in India.
“We are also working on the launch of newer treatment options, which we will bring to the market in the next few months. We have also ensured that supplies of our existing medicines continue uninterrupted and we continue to meet the market demand for all our markets,” the drug major’s Co-Chairman and Managing Director GV Prasad was quoted by the Indian Express.
Meanwhile, Dr Reddy’s CEO Erez Israeli explained that the company is also holding discussions with the Russian Direct Investment Fund (RDIF) for Sputnik light as well as quantities, rights and even assets permits for other countries.
Read Exclusive COVID-19 Coronavirus News updates, at MyNation.